[go: up one dir, main page]

MX2020009183A - Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). - Google Patents

Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).

Info

Publication number
MX2020009183A
MX2020009183A MX2020009183A MX2020009183A MX2020009183A MX 2020009183 A MX2020009183 A MX 2020009183A MX 2020009183 A MX2020009183 A MX 2020009183A MX 2020009183 A MX2020009183 A MX 2020009183A MX 2020009183 A MX2020009183 A MX 2020009183A
Authority
MX
Mexico
Prior art keywords
crystalline forms
sgc stimulator
present disclosure
sgc
stimulator
Prior art date
Application number
MX2020009183A
Other languages
English (en)
Inventor
Kwame W Nti-Addae
Thomas Storz
Leena Kumari Prasad
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65818696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020009183(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of MX2020009183A publication Critical patent/MX2020009183A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente descripción se relaciona con formas cristalinas de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1H- 1,2,4-triazol-5-il)im idazo[1,2-a]pirazina, que son útiles como estimuladores de guanilato ciclasa soluble (sGC). La presente descripción también provee composiciones farmacéuticamente aceptables que comprenden las formas cristalinas y métodos para usar las composiciones en el tratamiento de diversas afecciones.
MX2020009183A 2018-03-07 2019-03-07 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). MX2020009183A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862639846P 2018-03-07 2018-03-07
PCT/US2019/021080 WO2019173551A1 (en) 2018-03-07 2019-03-07 Crystalline forms of an sgc stimulator

Publications (1)

Publication Number Publication Date
MX2020009183A true MX2020009183A (es) 2020-10-08

Family

ID=65818696

Family Applications (5)

Application Number Title Priority Date Filing Date
MX2023004855A MX2023004855A (es) 2018-03-07 2019-03-07 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).
MX2020009183A MX2020009183A (es) 2018-03-07 2019-03-07 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).
MX2023004856A MX2023004856A (es) 2018-03-07 2019-03-07 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).
MX2023004858A MX2023004858A (es) 2018-03-07 2019-03-07 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).
MX2023004857A MX2023004857A (es) 2018-03-07 2019-03-07 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2023004855A MX2023004855A (es) 2018-03-07 2019-03-07 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2023004856A MX2023004856A (es) 2018-03-07 2019-03-07 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).
MX2023004858A MX2023004858A (es) 2018-03-07 2019-03-07 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).
MX2023004857A MX2023004857A (es) 2018-03-07 2019-03-07 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).

Country Status (21)

Country Link
US (3) US11466015B2 (es)
EP (1) EP3762389B1 (es)
JP (1) JP7423539B2 (es)
KR (1) KR102782810B1 (es)
CN (1) CN111836812A (es)
AU (1) AU2019231724B2 (es)
BR (1) BR112020018212A2 (es)
CA (1) CA3092683A1 (es)
CL (5) CL2020002284A1 (es)
CO (1) CO2020012493A2 (es)
CR (1) CR20200458A (es)
EA (1) EA202092109A1 (es)
ES (1) ES2980256T3 (es)
IL (1) IL276853B1 (es)
MA (1) MA54638A (es)
MX (5) MX2023004855A (es)
PE (1) PE20210124A1 (es)
PH (1) PH12020551394A1 (es)
SG (1) SG11202008641WA (es)
TW (1) TWI823903B (es)
WO (1) WO2019173551A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2980256T3 (es) 2018-03-07 2024-09-30 Tisento Therapeutics Inc Formas cristalinas de un estimulador SGC
US12220414B2 (en) * 2018-07-11 2025-02-11 Tisento Therapeutics Inc. Use of sGC stimulators for the treatment of mitochondrial disorders
WO2021195403A1 (en) * 2020-03-26 2021-09-30 Cyclerion Therapeutics, Inc. Deuterated sgc stimulators
WO2024131850A1 (zh) * 2022-12-21 2024-06-27 广东东阳光药业股份有限公司 氟取代的吲唑化合物的晶型及其用途
AU2023412238A1 (en) * 2022-12-21 2025-07-03 Sunshine Lake Pharma Co., Ltd. Crystal form of fluorine-substituted indazole compound and use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE69928260T2 (de) 1998-07-08 2006-07-20 Sanofi-Aventis Deutschland Gmbh Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
KR20100059952A (ko) 2007-09-06 2010-06-04 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 사이클라제 활성제
US7947664B2 (en) 2008-01-24 2011-05-24 Merck Sharp & Dohme Corp. Angiotensin II receptor antagonists
WO2010065275A1 (en) 2008-11-25 2010-06-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2010099054A2 (en) 2009-02-26 2010-09-02 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2011119518A1 (en) 2010-03-25 2011-09-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
BR112012030177B1 (pt) 2010-05-27 2019-08-27 Merck Sharp & Dohme composto ativador da guanilato ciclase solúvel, e, composição farmacêutica
EP3173407A1 (en) 2010-06-30 2017-05-31 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2012058132A1 (en) 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
RU2016101964A (ru) 2010-11-09 2018-11-21 Айронвуд Фармасьютикалз, Инк. СТИМУЛЯТОРЫ sGC
HK1212984A1 (en) 2012-11-30 2016-06-24 Astellas Pharma Inc Imidazopyridine compounds
CN105339368B (zh) 2013-06-04 2017-08-15 拜耳制药股份公司 3‑芳基‑取代的咪唑并[1,2‑a]吡啶及其用途
CN104327107A (zh) * 2013-10-17 2015-02-04 广东东阳光药业有限公司 一种氟喹诺酮类抗菌药物的制备方法
EP3152214B1 (en) 2014-06-04 2020-01-29 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
JP2017527604A (ja) 2014-09-17 2017-09-21 アイアンウッド ファーマシューティカルズ インコーポレイテッド ｓＧＣ刺激剤
CA2969265A1 (en) * 2014-12-02 2016-06-09 Bayer Pharma Aktiengesellschaft Substituted pyrazolo[1,5-a]pyridines and imidazo[1,2-a]pyrazines and their use
IL292968B2 (en) 2016-09-02 2025-10-01 Cyclerion Therapeutics Inc SCG racers merge on bicycles
ES2980256T3 (es) 2018-03-07 2024-09-30 Tisento Therapeutics Inc Formas cristalinas de un estimulador SGC

Also Published As

Publication number Publication date
KR20200128708A (ko) 2020-11-16
AU2019231724A1 (en) 2020-10-08
JP7423539B2 (ja) 2024-01-29
US12122782B2 (en) 2024-10-22
CL2021003536A1 (es) 2022-08-19
CL2021000301A1 (es) 2021-06-18
CL2021003531A1 (es) 2022-08-19
CN111836812A (zh) 2020-10-27
US20210115050A1 (en) 2021-04-22
JP2021515015A (ja) 2021-06-17
IL276853B1 (en) 2026-01-01
PH12020551394A1 (en) 2021-11-22
US11466015B2 (en) 2022-10-11
SG11202008641WA (en) 2020-10-29
MX2023004857A (es) 2023-11-24
CL2020002284A1 (es) 2020-11-27
ES2980256T3 (es) 2024-09-30
IL276853A (en) 2020-10-29
CL2021003530A1 (es) 2022-08-19
MX2023004856A (es) 2023-11-24
MX2023004858A (es) 2023-11-24
MA54638A (fr) 2021-11-10
WO2019173551A8 (en) 2020-06-11
MX2023004855A (es) 2023-11-24
AU2019231724B2 (en) 2024-06-27
TW201940487A (zh) 2019-10-16
CO2020012493A2 (es) 2020-10-30
EP3762389B1 (en) 2024-02-28
US20230095799A1 (en) 2023-03-30
US20250115611A1 (en) 2025-04-10
EA202092109A1 (ru) 2021-03-04
CR20200458A (es) 2020-11-09
CA3092683A1 (en) 2019-09-12
KR102782810B1 (ko) 2025-03-14
PE20210124A1 (es) 2021-01-19
EP3762389A1 (en) 2021-01-13
TWI823903B (zh) 2023-12-01
BR112020018212A2 (pt) 2020-12-29
WO2019173551A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
PH12020551394A1 (en) CRYSTALLINE FORMS OF AN sGC STIMULATOR
MX2020008237A (es) Inhibidores de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol de cgas para tratar enfermedades autoinflamatorias.
NZ744349A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
TN2019000110A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
MX2021001952A (es) Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met.
TN2019000107A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
PH12016502168A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
IL172192A0 (en) Pyridino [1,2 - a] pyrimidin - 4 - one compounds as anticancer agents
IL289164A (en) The history of imidazo[2,1-a)pyridinyl and their use in the treatment of diseases
PL373414A1 (en) 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands
NZ592641A (en) 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine, its salts, and uses in medical treatment
MX390132B (es) 7-bencil-4-(2-metilbencil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, sales de la misma y metodos de uso.
WO2004073628A3 (en) Novel compounds
MXPA03008423A (es) Agonistas del receptor nicotinico para el tratamiento de enfermedades inflamatorias.
WO2022058745A3 (en) Imidazo[1,2-a]pyridine compounds and their use in therapy
MX2025002794A (es) Compuestos citotoxicos de imidazo[1,2-a]piridina y su uso en terapia
WO2024059713A3 (en) Compositions of iboga alkaloids and methods of treatment
WO2015165933A3 (de) Imidazo[1,2-a]pyridine als stimulatoren der löslichen guanylatcyclase zur behandlung von kardiovaskulären erkrankungen
MX2021000683A (es) Derivados de imidazo[1,2-b]piridazina como inhibidores de trk.
MXPA05012082A (es) Compuestos como antagonistas del receptor crf1.
MX2023004924A (es) Nuevo tratamiento de la atrofia muscular espinal (sma).
PH12020551389A1 (en) Process for preparing soluble guanylate cyclase stimulators
MX2020005847A (es) Tratamiento del vsr con producto combinado.
MX2023008755A (es) Cristales de sal.
PH12021553174A1 (en) Polymorphs of a macrocyclic kinase inhibitor